Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
01:05pm, Friday, 01'st Aug 2025
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
06:36pm, Thursday, 31'st Jul 2025
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.32 per share a year ago.
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
04:05pm, Thursday, 31'st Jul 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Thursday, 24'th Jul 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on July 31, 2025.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
11:21am, Tuesday, 15'th Jul 2025
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
08:00am, Monday, 14'th Jul 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
01:45am, Monday, 30'th Jun 2025
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modu
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
05:37pm, Friday, 13'th Jun 2025
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guida
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinolog
New Strong Sell Stocks for May 29th
07:16am, Thursday, 29'th May 2025
CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
02:15pm, Tuesday, 06'th May 2025
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025.
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
08:34pm, Monday, 05'th May 2025
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrino
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
06:30pm, Monday, 05'th May 2025
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago.
